Previous 10 | Next 10 |
SAN CARLOS, Calif., April 09, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2019...
- Will support Sera’s Transition from clinical to commercial stage company - - Sera positioned for growth with several outcome study read-outs taking place in 2020 - SALT LAKE CITY, April 02, 2020 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., The Pregnancy Company...
SAN CARLOS, Calif., March 31, 2020 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data...
Company to Host a Conference Call with National Co-Principal Investigators on March 31, 2020 at 4:15 p.m. ET Fourth Quarter 2019 Financial Results to be Issued March 30, 2020 SAN CARLOS, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the develop...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
SAN CARLOS, Calif., Jan. 14, 2020 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for ...
Gainers: Adaptimmune Therapeutics (NASDAQ: ADAP ) +242% . More news on: Adaptimmune Therapeutics plc, Aethlon Medical, Inc., BioCardia, Inc., Stocks on the move, Read more ...
Ultra-thinly traded nano cap BioCardia ( OTCQB:BCDA +14.7% ) is up on more than double volume, a modest 27K shares, in reaction to its receipt of three new patents for its technologies. More news on: BioCardia, Inc., Healthcare stocks news, Stocks on the move, Read more ...
SAN CARLOS, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [NASDAQ: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the issuance of three new patents for the company’s technologies in...
Gainers: ChemoCentryx (NASDAQ: CCXI ) +261% . More news on: ChemoCentryx, Inc., Akerna Corp., Proteostasis Therapeutics, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the confirmatory Phase 3 trial of its autologous CardiAMP cell therap...
SUNNYVALE, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Unites States Patent Office has granted Patent No: 12,036,371 ti...
SUNNYVALE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Unites States Patent Office has granted Patent No: ...